Cantor Fitzgerald Expects Higher Earnings for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Kura Oncology in a research note issued on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($2.21) per share for the year, up from their previous estimate of ($2.94). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million.

Several other analysts have also recently commented on KURA. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Jefferies Financial Group dropped their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Scotiabank decreased their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Trading Up 8.0 %

NASDAQ:KURA opened at $7.85 on Friday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $6.79 and a 12 month high of $23.48. The company has a market cap of $633.93 million, a PE ratio of -3.33 and a beta of 0.85. The company has a 50 day simple moving average of $7.81 and a two-hundred day simple moving average of $12.58.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its holdings in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Rhumbline Advisers raised its holdings in shares of Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock valued at $871,000 after purchasing an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock worth $120,000 after purchasing an additional 2,285 shares during the period. Finally, MetLife Investment Management LLC boosted its position in shares of Kura Oncology by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock worth $390,000 after acquiring an additional 2,776 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.